Adynovate in combination with Mypkfit offers personalized treatment and enables HCPs and patients to monitor factor levels from home and help achieve optimum QOL outcomes
Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
Huntington Medical Research Institutes present first-of-its-kind study examining impact of erectile dysfunction drugs on major adverse cardiovascular events and mortality
Q1 net sales increased by 12.2% to € 5,198 million compared with the year-earlier quarter
For the first time in India – fast, precise and efficient calibration of multi-channel micropipettes
Boehringer Ingelheim continues to innovate to enhance the customer experience and improve animal health and well-being
AKS-452 is currently undergoing Phase II/III clinical testing in India as a primary vaccine; submission for Emergency Use Authorization (EUA) expected by Q3 2022
Image and data analysis of rich spatial information from mIF images can accelerate tissue biomarker discovery and validation
NextSWAB is currently optimized for nasal sample collection with validation for other sample types ongoing
ArisGlobal acquires Boehringer Ingelheim’s Benefit-Risk Analytic System (BRASS), a software solution designed to support causal analysis of drug safety data in a highly regulated environment
Subscribe To Our Newsletter & Stay Updated
